We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Senate Letter Seeks Public Input on Gilead Pricing Concerns
Senate Letter Seeks Public Input on Gilead Pricing Concerns
With congressional efforts to pressure Gilead Sciences into lowering the price of two hepatitis C drugs floundering, members of the Senate Finance Committee are taking their concerns directly to the public.